KPV in experimental colitis

Study record

Population

Human-derived intestinal and T-cell lines; female C57BL/6 mice aged 8 weeks.

Read source · Full-text reportMaterials and methods — Cell culture and Animals

Formulation

KPV reagent was purchased from Biopeptide; radiolabeled KPV for uptake assays came from Sibtech. These are experimental reagents, not evidence for a commercial KLOW formulation.

Read source · Supplementary materialMaterials and methods — Reagents, PDF page 1

Route

Drinking water in mice; exposure in cell culture.

Read source · Full-text reportMaterials and methods; Figures 6 and 8

Dose & frequency

The in-vivo experiments used a KPV concentration of 100 μM. Concentration is not a body-weight dose; no human or KLOW regimen is established.

Read source · Full-text reportDiscussion — rationale for in-vivo concentration

Study design

Cell experiments and DSS/TNBS mouse-colitis models with KPV and control groups.

Read source · Full-text reportMaterials and methods; Figures 6 and 8

Duration

Inflammation was assessed 8 days after DSS treatment or 48 hours after TNBS administration. These are model-specific assessment times, not human treatment cycles.

Read source · Full-text reportMaterials and methods — Induction of colitis

Reported findings

Reduced inflammatory signaling in cells and inflammatory measures in mouse models.

Read source · Full-text reportResults; Figures 1, 6–8

Adverse events

Human safety was not evaluated: this was a cell and mouse study. Experimental inflammation outcomes do not establish clinical safety.

Read source · Full-text reportMaterials and methods — Cell culture, Animals and Induction of colitis

Monitoring

Experimental inflammation assessment used histology and pro-inflammatory cytokine expression. These are research endpoints, not human safety monitoring.

Read source · Full-text reportAbstract Methods; Materials and methods — Induction of colitis